Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mecha Limitations

Frontiers in Oncology

8, 86

DOI: 10.3389/fonc.2018.00086

Citation Report

#	Article	IF	Citations
1	NF-Î°B Signaling in Targeting Tumor Cells by Oncolytic Virusesâ€"Therapeutic Perspectives. Cancers, 2018, 10, 426.	1.7	17
2	Bystander T Cells: A Balancing Act of Friends and Foes. Trends in Immunology, 2018, 39, 1021-1035.	2.9	79
3	Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry. Pharmaceutics, 2018, 10, 260.	2.0	6
4	Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy. Frontiers in Immunology, 2018, 9, 2878.	2.2	4
5	Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Frontiers in Pharmacology, 2018, 9, 1300.	1.6	602
6	Receptor-Targeted Glial Brain Tumor Therapies. International Journal of Molecular Sciences, 2018, 19, 3326.	1.8	34
7	Creating molecules that modulate immune responses. Nature Reviews Chemistry, 2018, 2, 184-193.	13.8	14
8	Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changinâ€™. Clinical Lung Cancer, 2018, 19, 461-463.	1.1	2
9	Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody. Cancer Biology and Therapy, 2019, 20, 109-121.	1.5	19
11	Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics. Cancer Biology and Medicine, 2019, 16, 247.	1.4	21
12	The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer. Cancers, 2019, 11, 1205.	1.7	57
13	Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. Medical Sciences (Basel, Switzerland), 2019, 7, 83.	1.3	21
14	Neoadjuvant therapy of locally/regionally advanced melanoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986695.	1.4	21
15	Translational and basic science opportunities in palliative care and radiation oncology. Annals of Palliative Medicine, 2019, 8, 326-336.	0.5	0
16	Lipidic Aminoglycoside Derivatives: A New Class of Immunomodulators Inducing a Potent Innate Immune Stimulation. Advanced Science, 2019, 6, 1900288.	5.6	11
17	ESR1 mutations in breast cancer. Cancer, 2019, 125, 3714-3728.	2.0	154
18	Enhanced early immune response of leptospiral outer membrane protein LipL32 stimulated by narrow band mid-infrared exposure. Journal of Photochemistry and Photobiology B: Biology, 2019, 198, 111560.	1.7	6
19	Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?. Cancers, 2019, 11, 984.	1.7	78

#	Article	IF	Citations
20	Nanoenabled Reversal of IDO1-Mediated Immunosuppression Synergizes with Immunogenic Chemotherapy for Improved Cancer Therapy. Nano Letters, 2019, 19, 5356-5365.	4.5	87
21	PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer. Cancers, 2019, 11, 1050.	1.7	50
22	MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications. Pathology Research and Practice, 2019, 215, 152552.	1.0	12
23	Metabolic flexibility in melanoma: A potential therapeutic target. Seminars in Cancer Biology, 2019, 59, 187-207.	4.3	62
24	Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer. Frontiers in Immunology, 2019, 10, 1351.	2.2	60
25	Cell signaling and cancer: a mechanistic insight into drug resistance. Molecular Biology Reports, 2019, 46, 5645-5659.	1.0	63
26	Immune Checkpoints of the B7 Family. Part 2. Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors. Russian Journal of Bioorganic Chemistry, 2019, 45, 321-334.	0.3	9
27	Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacological Reviews, 2019, 71, 671-697.	7.1	13
28	The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy . OncoTargets and Therapy, 2019, Volume 12, 8437-8445.	1.0	141
29	Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells. Vaccines, 2019, 7, 149.	2.1	63
30	Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review. Oncology Reviews, 2019, 13, 425.	0.8	14
31	Knowledge is powerâ€"Rational design of cancer immunotherapy. Journal of Leukocyte Biology, 2019, 106, 1003-1006.	1.5	0
32	Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer. Cytokine and Growth Factor Reviews, 2019, 49, 1-9.	3.2	11
33	Tumor Immunosurveillance and Immunotherapies: A Fresh Look from Intravital Imaging. Trends in Immunology, 2019, 40, 1022-1034.	2.9	39
34	The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. Experimental Hematology and Oncology, 2019, 8, 26.	2.0	58
35	Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy. Critical Reviews in Immunology, 2019, 39, 93-103.	1.0	16
36	Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity. Seminars in Oncology, 2019, 46, 385-392.	0.8	11
37	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies, 2019, 8, 51.	1.2	32

#	Article	IF	Citations
38	Identification of 15 T Cell Restricted Genes Evaluates T Cell Infiltration of Human Healthy Tissues and Cancers and Shows Prognostic and Predictive Potential. International Journal of Molecular Sciences, 2019, 20, 5242.	1.8	7
39	Invariant NKT Cell-Mediated Modulation of ILC1s as a Tool for Mucosal Immune Intervention. Frontiers in Immunology, 2019, 10, 1849.	2.2	6
40	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes and Diseases, 2019, 6, 232-246.	1.5	44
41	Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives. OncoImmunology, 2019, 8, e1644109.	2.1	23
42	The effects and safety of PDâ€1/PDâ€L1 inhibitors on head and neck cancer: A systematic review and metaâ€analysis. Cancer Medicine, 2019, 8, 5969-5978.	1.3	26
43	Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC. Russian Journal of Bioorganic Chemistry, 2019, 45, 225-240.	0.3	6
44	Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies . Cancer Management and Research, 2019, Volume 11, 8095-8100.	0.9	7
45	A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control. OncoImmunology, 2019, 8, 1652539.	2.1	45
46	Digitaldlsorter: Deep-Learning on scRNA-Seq to Deconvolute Gene Expression Data. Frontiers in Genetics, 2019, 10, 978.	1.1	22
47	Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. Cells, 2019, 8, 1083.	1.8	153
48	Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1065-1073.	0.4	79
49	Cardiotoxicity from immune checkpoint inhibitors. IJC Heart and Vasculature, 2019, 25, 100420.	0.6	79
50	Current Perspectives in Cancer Immunotherapy. Cancers, 2019, 11, 1472.	1.7	149
51	[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the antiâ€“CTLA-4 antibody in a mouse model. PLoS ONE, 2019, 14, e0222280.	1.1	23
52	Potential Therapies for Infectious Diseases Based on Targeting Immune Evasion Mechanisms That Pathogens Have in Common With Cancer Cells. Frontiers in Cellular and Infection Microbiology, 2019, 9, 25.	1.8	6
53	Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patientsâ€™ response to cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2019, 135, 21-29.	2.0	23
54	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. Cancer Chemotherapy and Pharmacology, 2019, 84, 227-240.	1.1	50
55	Combined analysis of keratinocyte cancers identifies novel genome-wide loci. Human Molecular Genetics, 2019, 28, 3148-3160.	1.4	46

#	Article	IF	Citations
56	Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 828-835.	0.4	46
57	Immune checkpoint inhibitors in malignancy. Australian Prescriber, 2019, 42, 62.	0.5	24
58	Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. Frontiers in Immunology, 2019, 10, 925.	2.2	288
59	Spectro-electrochemical assessments of DNA/BSA interactions, cytotoxicity, radical scavenging and pharmacological implications of biosensitive and biologically active morpholine-based metal(<scp>ii</scp>) complexes: a combined experimental and computational investigation. RSC Advances, 2019, 9, 14220-14241.	1.7	39
60	Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma. Journal of Medical Virology, 2019, 91, 1702-1706.	2.5	37
61	Helper-like innate lymphoid cells and cancer immunotherapy. Seminars in Immunology, 2019, 41, 101274.	2.7	25
62	Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 2296.	1.8	35
63	Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Letters, 2019, 457, 168-179.	3.2	148
64	Optimal Timing and Sequence of Immunotherapy When Combined with Stereotactic Radiosurgery in the Treatment of Brain Metastases. World Neurosurgery, 2019, 127, 397-404.	0.7	17
65	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008.	3.4	526
66	Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy . Biologics: Targets and Therapy, 2019, Volume 13, 33-51.	3.0	115
67	Polyphenols as Immunomodulatory Compounds in the Tumor Microenvironment: Friends or Foes?. International Journal of Molecular Sciences, 2019, 20, 1714.	1.8	54
68	Modulating inflammation for cancer therapy. Journal of Experimental Medicine, 2019, 216, 1234-1243.	4.2	108
69	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Frontiers in Immunology, 2019, 10, 453.	2.2	177
70	Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. Cancers, 2019, 11, 305.	1.7	51
71	Preclinical Development of a WT1 Oral Cancer Vaccine Using a Bacterial Vector to Treat Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2019, 18, 980-990.	1.9	18
72	Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2019, 9, 122.	1.3	63
73	Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PDâ€1 receptor. International Journal of Cancer, 2019, 145, 1660-1668.	2.3	65

#	Article	IF	Citations
74	Anticancer Activities of Natural and Synthetic Peptides. Advances in Experimental Medicine and Biology, 2019, 1117, 131-147.	0.8	59
75	Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 156.	3.5	170
76	Resveratrol antagonizes thyroid hormone-induced expression of checkpoint and proliferative genes in oral cancer cells. Journal of Dental Sciences, 2019, 14, 255-262.	1.2	26
77	Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. British Journal of Haematology, 2019, 186, 220-233.	1.2	17
78	Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade. Frontiers in Immunology, 2019, 10, 467.	2.2	122
79	Perspectives on immunotherapy via oncolytic viruses. Infectious Agents and Cancer, 2019, 14, 5.	1.2	24
80	Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. BioMed Research International, 2019, 2019, 1-22.	0.9	9
81	Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa. Frontiers in Medicine, 2019, 6, 249.	1.2	18
82	Immunotherapy: A Challenge of Breast Cancer Treatment. Cancers, 2019, 11, 1822.	1.7	106
83	From Super-Enhancer Non-coding RNA to Immune Checkpoint: Frameworks to Functions. Frontiers in Oncology, 2019, 9, 1307.	1.3	29
84	The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacology Research and Perspectives, 2019, 7, e00535.	1.1	154
85	Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab. Journal of Immunotherapy, 2019, 42, 136-141.	1.2	6
86	Pair Correlation Analysis Maps the Dynamic Two-Dimensional Organization of Natural Killer Cell Receptors at the Synapse. ACS Nano, 2019, 13, 14274-14282.	7.3	14
87	Increased Neutrophil Surface PD-L1 Expression in Tobacco Smokers: Consequences for Antiâ€“PD-1 Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e48-e49.	0.9	1
88	Checkpoint Inhibitorâ€“Associated Autoimmunity. Journal of Clinical Rheumatology, 2019, Publish Ahead of Print, .	0.5	0
89	Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug. PLoS ONE, 2019, 14, e0226869.	1.1	12
90	Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients. Ophthalmic Plastic and Reconstructive Surgery, 2019, 35, 50-52.	0.4	37
91	In vivo molecular imaging for immunotherapy using ultra-bright near-infrared-IIb rare-earth nanoparticles. Nature Biotechnology, 2019, 37, 1322-1331.	9.4	398

#	Article	IF	Citations
92	In-situ vaccination using focused ultrasound heating and anti-CD-40 agonistic antibody enhances T-cell mediated local and abscopal effects in murine melanoma. International Journal of Hyperthermia, 2019, 36, 64-73.	1.1	29
93	Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer. Medicine (United States), 2019, 98, e16324.	0.4	2
94	Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Medicine (United States), 2019, 98, e18054.	0.4	26
95	An image informatics pipeline for imaging mass cytometry to characterize the immune landscape in pre- and on-treatment immune therapy and its application in recurrent platinium-resistant epithelial ovarian cancer. , 2019, , .		2
96	Herbal Medicines Attenuate PD-L1 Expression to Induce Anti-Proliferation in Obesity-Related Cancers. Nutrients, 2019, 11, 2979.	1.7	13
97	Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?. International Journal of Molecular Sciences, 2019, 20, 24.	1.8	100
98	Natural killer cellâ€“mediated anticancer effects of an arabinogalactan derived from rice hull in CT26 colon cancerâ€“bearing mice. International Journal of Biological Macromolecules, 2019, 124, 368-376.	3.6	10
99	In situ vaccination with biocompatibility controllable immuno-sensitizer inducing antitumor immunity. Biomaterials, 2019, 197, 32-40.	5.7	16
100	Revolutionizing treatment of advanced melanoma with immunotherapy. Surgical Oncology, 2019, , 101180.	0.8	12
101	Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. Future Oncology, 2019, 15, 349-358.	1.1	34
102	Engineering lymphocytes with RNAi. Advanced Drug Delivery Reviews, 2019, 141, 55-66.	6.6	21
103	Immune Checkpoint Inhibitor Therapy in HIV-Positive Patients with Advanced-Stage Cancer: a Golden Card to Be Played?. Pathology and Oncology Research, 2020, 26, 1357-1358.	0.9	0
104	Virusâ€like particles for vaccination against cancer. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1579.	3.3	74
105	Oral melanomas in HIV-positive patients: Report of two cases and review of the literature. Oral Oncology, 2020, 101, 104375.	0.8	2
106	Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Seminars in Cancer Biology, 2020, 65, 13-27.	4.3	170
107	Inhibitors of HSP90 in melanoma. Apoptosis: an International Journal on Programmed Cell Death, 2020, 25, 12-28.	2.2	35
108	New Approaches on Cancer Immunotherapy. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036863.	2.9	17
109	Interferon Î± in cancer immunoediting: From elimination to escape. Scandinavian Journal of Immunology, 2020, 91, e12863.	1.3	31

#	Article	IF	Citations
110	Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Science China Life Sciences, 2020, 63, 180-205.	2.3	40
111	Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice. Journal of Controlled Release, 2020, 318, 270-278.	4.8	30
112	Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy. , 2020, 207, 107456.		42
113	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 541-551.	3.3	66
114	Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy. Acta Biomaterialia, 2020, 104, 147-157.	4.1	76
115	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. Oncologist, 2020, 25, e528-e535.	1.9	44
116	Trypanosoma cruzi calreticulin: In vitro modulation of key immunogenic markers of both canine tumors and relevant immune competent cells. Immunobiology, 2020, 225, 151892.	0.8	6
117	Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model. ACS Biomaterials Science and Engineering, 2020, 6, 2659-2667.	2.6	15
118	Interleukin-38 in colorectal cancer: a potential role in precision medicine. Cancer Immunology, Immunotherapy, 2020, 69, 69-79.	2.0	18
119	Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients. Transplantation, 2020, 104, 1041-1047.	0.5	30
120	Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response. International Journal of Molecular Sciences, 2020, 21, 157.	1.8	136
121	Treatment-related adverse events and response rate to immune checkpoint inhibition. Journal of International Medical Research, 2020, 48, 030006051988645.	0.4	0
122	Coding transcriptome analyses reveal altered functions underlying immunotolerance of PEG-fused rat sciatic nerve allografts. Journal of Neuroinflammation, 2020, 17, 287.	3.1	2
123	Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Frontiers in Immunology, 2020, 11, 568759.	2.2	79
124	The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. Life, 2020, 10, 219.	1.1	11
125	CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer. Cancer Letters, 2020, 495, 12-21.	3.2	58
126	Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer. Seminars in Radiation Oncology, 2020, 30, 273-280.	1.0	39
127	Therapy of Primary Liver Cancer. Innovation(China), 2020, 1, 100032.	5.2	46

#	Article	IF	Citations
128	TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy. Journal of Biopharmaceutical Statistics, 2020, 30, 979-992.	0.4	11
129	From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. Cancers, 2020, 12, 3057.	1.7	50
130	Colorectal Cancer Immunotherapy: Options and Strategies. Frontiers in Immunology, 2020, 11, 1624.	2.2	207
131	The Immunotherapy Landscape in Renal Cell Carcinoma. BioDrugs, 2020, 34, 733-748.	2.2	27
132	Probing Protein Conformation Destabilization in Sterile Liquid Formulations through the Formation of 3,4-Dihydroxyphenylalanine. Molecular Pharmaceutics, 2020, 17, 3783-3793.	2.3	2
133	Crossâ€Linkâ€Functionalized Nanoparticles for Rapid Excretion in Nanotheranostic Applications. Angewandte Chemie, 2020, 132, 20733-20741.	1.6	6
134	The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3207-e3223.	1.8	30
135	A Review of the Mechanisms and Clinical Implications of Precision Cancer Therapyâ€"Related Toxicity: A Primer for the Radiologist. American Journal of Roentgenology, 2020, 215, 770-780.	1.0	4
136	Tet2 at the interface between cancer and immunity. Communications Biology, 2020, 3, 667.	2.0	50
137	Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma. International Journal of Molecular Sciences, 2020, 21, 8721.	1.8	8
138	Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma . ImmunoTargets and Therapy, 2020, Volume 9, 273-288.	2.7	9
139	Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies. Frontiers in Oncology, 2020, 10, 559596.	1.3	9
140	Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers, 2020, 12, 3515.	1.7	5
141	Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities. Genes and Development, 2020, 34, 1577-1598.	2.7	19
142	Modelling of Immune Checkpoint Network Explains Synergistic Effects of Combined Immune Checkpoint Inhibitor Therapy and the Impact of Cytokines in Patient Response. Cancers, 2020, 12, 3600.	1.7	9
143	Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 608969.	1.8	29
144	Understanding the Mechanisms of Diet and Outcomes in Colon, Prostate, and Breast Cancer; Malignant Gliomas; and Cancer Patients on Immunotherapy. Nutrients, 2020, 12, 2226.	1.7	13
145	Correlation Between Tumor-Associated Macrophage and Immune Checkpoint Molecule Expression and Its Prognostic Significance in Cutaneous Melanoma. Journal of Clinical Medicine, 2020, 9, 2500.	1.0	19

#	Article	IF	Citations
146	A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications. Frontiers in Immunology, 2020, 11, 1612.	2.2	21
147	Targeting telomerase for cancer therapy. Oncogene, 2020, 39, 5811-5824.	2.6	122
148	Sarcoidosis-like disease mimicking metastases during adjuvant ipilimumab therapy in advanced melanoma patient: CT scan and MRI help in managing difficult clinical decision. BJR|case Reports, 2020, 6, 20190065.	0.1	5
149	Phytochemical Targeting of STAT3 Orchestrated Lipid Metabolism in Therapy-Resistant Cancers. Biomolecules, 2020, 10, 1118.	1.8	10
150	The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis. Translational Cancer Research, 2020, 9, 3804-3818.	0.4	7
151	PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5337.	1.8	26
152	Metabolic Modulation of the Tumor Microenvironment Leads to Multiple Checkpoint Inhibition and Immune Cell Infiltration. ACS Nano, 2020, 14, 11055-11066.	7.3	76
153	Using Tâ€cell repertoire profiles as predictor in a primary mucosal melanoma. Clinical and Translational Medicine, 2020, 10, e136.	1.7	3
154	Different patterns of treatmentâ€related adverse events of programmed cell deathâ€1 and its ligandâ€1 inhibitors in different cancer types: A metaâ€analysis and systemic review of clinical trials. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e160-e178.	0.7	6
155	Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells. Cancers, 2020, 12, 2204.	1.7	12
156	Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cellular Oncology (Dordrecht), 2020, 43, 1203-1214.	2.1	73
157	Role of Immunotherapy in Advanced Gastroesophageal Cancer. Current Oncology Reports, 2020, 22, 112.	1.8	5
158	Injectable Reactive Oxygen Species-Responsive SN38 Prodrug Scaffold with Checkpoint Inhibitors for Combined Chemoimmunotherapy. ACS Applied Materials & Interfaces, 2020, 12, 50248-50259.	4.0	33
159	NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 7802.	1.8	42
160	Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours. Veterinary Immunology and Immunopathology, 2020, 230, 110142.	0.5	18
161	Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential. Expert Opinion on Therapeutic Targets, 2020, 24, 1251-1262.	1.5	16
162	Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade. Frontiers in Immunology, 2020, 11, 578349.	2.2	11
163	Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model. , 2020, 8, e001141.		31

#	Article	IF	Citations
164	iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery. Polymers, 2020, 12, 1906.	2.0	45
165	Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. International Journal of Molecular Sciences, 2020, 21, 6885.	1.8	156
166	Moderate static magnetic fields enhance antitumor CD8+ T cell function by promoting mitochondrial respiration. Scientific Reports, 2020, 10, 14519.	1.6	7
167	Cancer immunotherapyâ€“related adverse events: causes and challenges. Supportive Care in Cancer, 2020, 28, 6111-6117.	1.0	22
168	Kindlin-3 loss curbs chronic myeloid leukemia in mice by mobilizing leukemic stem cells from protective bone marrow niches. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24326-24335.	3.3	15
169	EZH2 inhibition: aÂpromisingÂstrategy to prevent cancer immune editing. Epigenomics, 2020, 12, 1457-1476.	1.0	37
170	Hepatocellular Carcinomaâ€”The Influence of Immunoanatomy and the Role of Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 6757.	1.8	9
171	Updated Understanding of Cancer as a Metabolic and Telomere-Driven Disease, and Proposal for Complex Personalized Treatment, a Hypothesis. International Journal of Molecular Sciences, 2020, 21, 6521.	1.8	6
172	Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. Pharmaceutics, 2020, 12, 758.	2.0	6
173	Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy . International Journal of Nanomedicine, 2020, Volume 15, 5279-5288.	3.3	18
174	The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. Frontiers in Oncology, 2020, 10, 524205.	1.3	31
175	Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 558572.	1.3	12
176	B Cells versus T Cells in the Tumor Microenvironment of Malignant Lymphomas. Are the Lymphocytes Playing the Roles of Muhammad Ali versus George Foreman in Zaire 1974?. Journal of Clinical Medicine, 2020, 9, 3412.	1.0	2
177	Plants derived therapeutic strategies targeting chronic respiratory diseases: Chemical and immunological perspective. Chemico-Biological Interactions, 2020, 325, 109125.	1.7	40
178	Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis. , 2020, 8, e000480.		4
179	Thymic Function Associated With Cancer Development, Relapse, and Antitumor Immunity â€“ A Mini-Review. Frontiers in Immunology, 2020, 11, 773.	2.2	27
180	Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers, 2020, 6, 38.	18.1	684
181	Rational Design of Polyglutamic Acid Delivering an Optimized Combination of Drugs Targeting Mutated BRAF and MEK in Melanoma. Advanced Therapeutics, 2020, 3, 2000028.	1.6	9

#	Article	IF	Citations
182	Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13428-13436.	3.3	51
183	Nanoemulsions as Delivery Systems for Poly-Chemotherapy Aiming at Melanoma Treatment. Cancers, 2020, 12, 1198.	1.7	25
184	Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 709-722.	1.9	6
185	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. , 2020, 8, e000538.		19
186	Co-inhibitory receptors, transcription factors and tolerance. International Immunopharmacology, 2020, 84, 106572.	1.7	3
187	Blood and Cancer: Cancer Stem Cells as Origin of Hematopoietic Cells in Solid Tumor Microenvironments. Cells, 2020, 9, 1293.	1.8	19
188	Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression. Gene, 2020, 754, 144888.	1.0	24
189	Integrating context of tumor biology and vaccine design to shape multidimensional immunotherapies. Future Drug Discovery, 2020, 2, FDD25.	0.8	1
190	Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns. Pharmacogenomics, 2020, 21, 705-720.	0.6	9
191	NF-Î°B and Its Role in Checkpoint Control. International Journal of Molecular Sciences, 2020, 21, 3949.	1.8	45
192	Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment. Acta Pharmaceutica Sinica B, 2020, 10, 2110-2124.	5.7	80
193	Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy. Pharmacological Research, 2020, 159, 104980.	3.1	36
194	Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. Frontiers in Immunology, 2020, 11, 1469.	2.2	58
195	Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapyâ€"Real-World Clinical Impressions and Comparative Review of the Literature. Frontiers in Oncology, 2020, 10, 808.	1.3	11
196	The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy. Frontiers in Oncology, 2020, 10, 899.	1.3	44
197	Immune checkpoint inhibitors and diabetes. Practical Diabetes, 2020, 37, 96-100.	0.1	1
198	Cautious Optimismâ€"The Current Role of Immunotherapy in Gastrointestinal Cancers. Current Oncology, 2020, 27, 59-68.	0.9	4
199	Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy. Frontiers in Immunology, 2020, 11, 283.	2.2	46

#	Article	IF	Citations
200	Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy, 2020, 5, 22.	7.1	853
201	Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. Diagnostics, 2020, 10, 146.	1.3	56
202	Multi-scale cellular engineering: From molecules to organ-on-a-chip. APL Bioengineering, 2020, 4, 010906.	3.3	8
203	NK Cell-Based Immune Checkpoint Inhibition. Frontiers in Immunology, 2020, 11, 167.	2.2	211
204	Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. Cancer Letters, 2020, 478, 56-69.	3.2	32
205	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and antiâ€“PD-1 antibody in patients with mesothelioma and mouse tumor models. Science Translational Medicine, 2020, 12, .	5.8	28
206	Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer. Frontiers in Immunology, 2020, 11, 1184.	2.2	65
207	IL-34, IL-36 and IL-38 in colorectal cancerâ€"key immunoregulators of carcinogenesis. Biophysical Reviews, 2020, 12, 925-930.	1.5	20
208	Gut microbiome, big data and machine learning to promote precision medicine for cancer. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 635-648.	8.2	172
209	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Seminars in Cancer Biology, 2022, 79, 18-43.	4.3	35
210	Dendritic Cells and Their Roles in Anti-Tumour Immunity. , 2020, , .		0
211	Soluble immune checkpoints CTLAâ€4, HLAâ€G, PDâ€1, and PDâ€L1 are associated with endometriosisâ€related infertility. American Journal of Reproductive Immunology, 2020, 84, e13296.	1.2	19
212	Regulatory lymphocytes: the dice that resolve the tumor endgame. Applied Cancer Research, 2020, 40, .	1.0	7
213	Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. Cancers, 2020, 12, 1826.	1.7	46
214	Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts. Frontiers in Medicine, 2020, 7, 264.	1.2	10
215	Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. Gynecologic Oncology, 2020, 158, 531-537.	0.6	8
216	Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent/metastatic thymic carcinoma patient: a case report. European Heart Journal - Case Reports, 2020, 4, 1-8.	0.3	28
217	Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma. Cancer Immunology, Immunotherapy, 2020, 69, 1087-1099.	2.0	8

#	Article	IF	Citations
218	Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers, 2020, 12, 482.	1.7	112
219	The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment. Journal of Clinical Medicine, 2020, 9, 519.	1.0	26
220	Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. Science Immunology, 2020, 5, .	5.6	39
222	T cells, aging and senescence. Experimental Gerontology, 2020, 134, 110887.	1.2	100
223	The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia. Expert Opinion on Biological Therapy, 2020, 20, 799-812.	1.4	5
224	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 91.	1.3	112
225	Resistance to Checkpoint Inhibition in Cancer Immunotherapy. Translational Oncology, 2020, 13, 100738.	1.7	173
226	Rose Bengalâ€“Amphiphilic Peptide Conjugate for Enhanced Photodynamic Therapy of Malignant Melanoma. Journal of Medicinal Chemistry, 2020, 63, 1328-1336.	2.9	25
227	Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles. Cancers, 2020, 12, 144.	1.7	60
228	Using curcumin to turn the innate immune system against cancer. Biochemical Pharmacology, 2020, 176, 113824.	2.0	18
229	Immune Suppression Mediated by STAT4 Deficiency Promotes Lymphatic Metastasis in HNSCC. Frontiers in Immunology, 2019, 10, 3095.	2.2	22
230	Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 87-96.	1.5	5
231	Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis. Medicine (United States), 2020, 99, e18701.	0.4	1
232	TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Therapy, 2020, 27, 841-853.	2.2	94
233	The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors. Biomolecules, 2020, 10, 666.	1.8	29
234	A review of the imaging manifestations of immune check point inhibitor toxicities. Clinical Imaging, 2020, 64, 70-79.	0.8	9
235	Neurological adverse effects due to programmed death 1 (PD-1) inhibitors. Journal of Neuro-Oncology, 2020, 148, 291-297.	1.4	8
236	Immunogenic clearance-mediated cancer vaccination. , 2020, , 549-568.		1

#	Article	IF	Citations
237	Interleukin-33 pretreatment promotes metastatic growth of murine melanoma by reducing the cytotoxic capacity of CD8+ T cells and enhancing regulatory T cells. Cancer Immunology, Immunotherapy, 2020, 69, 1461-1475.	2.0	11
238	The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence. Cancer Treatment Reviews, 2020, 86, 102011.	3.4	31
239	Thermosensitive hydrogels as sustained drug delivery system for CTLA-4 checkpoint blocking antibodies. Journal of Controlled Release, 2020, 323, 1-11.	4.8	47
240	Hypoxia regulates the differentiation and anti-tumor effector functions of Î³ÎT cells in oral cancer. Clinical and Experimental Immunology, 2020, 201, 40-57.	1.1	26
241	A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Science Advances, 2020, 6, eaaw6071.	4.7	152
242	Novel Genetic Melanoma Vaccines Based on Induced Pluripotent Stem Cells or Melanosphere-Derived Stem-Like Cells Display High Efficacy in a murine Tumor Rejection Model. Vaccines, 2020, 8, 147.	2.1	10
243	A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice. Cancers, 2020, 12, 1015.	1.7	13
244	Arginase and its mechanisms in Leishmania persistence. Parasite Immunology, 2020, 42, e12722.	0.7	32
245	TNF-Î± inhibitor reduces drug-resistance to anti-PD-1: A mathematical model. PLoS ONE, 2020, 15, e0231499.	1.1	9
246	Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk. Frontiers in Oncology, 2020, 10, 324.	1.3	76
247	Emerging role of microbiota in immunomodulation and cancer immunotherapy. Seminars in Cancer Biology, 2021, 70, 37-52.	4.3	19
248	Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. International Immunology, 2021, 33, 7-15.	1.8	79
249	Immunotherapies in cutaneous pathologies: an overview. Drug Discovery Today, 2021, 26, 248-255.	3.2	10
250	CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharmaceutica Sinica B, 2021, 11, 1129-1147.	5.7	47
251	FAPâ€Targeted Photodynamic Therapy Mediated by Ferritin Nanoparticles Elicits an Immune Response against Cancer Cells and Cancer Associated Fibroblasts. Advanced Functional Materials, 2021, 31, 2007017.	7.8	37
252	Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC. Cancer Immunology, Immunotherapy, 2021, 70, 189-202.	2.0	82
253	Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond. Cell Biology International, 2021, 45, 18-53.	1.4	8
254	Recent Progress in the Synergistic Combination of Nanoparticleâ€Mediated Hyperthermia and Immunotherapy for Treatment of Cancer. Advanced Healthcare Materials, 2021, 10, e2001415.	3.9	37

#	Article	IF	Citations
255	Prediction of CD28-CD86 protein complex structure using different level of resolution approach. Journal of Molecular Graphics and Modelling, 2021, 103, 107802.	1.3	4
256	Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies. Molecular Cancer Therapeutics, 2021, 20, 121-131.	1.9	37
257	Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease. Ophthalmology and Therapy, 2021, 10, 5-12.	1.0	5
258	DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy. Cancer Genetics, 2021, 252-253, 6-24.	0.2	28
259	Usefulness of IL-21, IL-7, and IL-15 conditioned media for expansion of antigen-specific CD8+ T cells from healthy donor-PBMCs suitable for immunotherapy. Cellular Immunology, 2021, 360, 104257.	1.4	5
260	Microneedles for painless transdermal immunotherapeutic applications. Journal of Controlled Release, 2021, 330, 185-217.	4.8	131
261	HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins. Cell Chemical Biology, 2021, 28, 158-168.e5.	2.5	42
262	Human immunology and immunotherapy: main achievements and challenges. Cellular and Molecular Immunology, 2021, 18, 805-828.	4.8	96
263	Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer. Carcinogenesis, 2021, 42, 38-47.	1.3	46
264	Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies. Chemical Science, 2021, 12, 9759-9769.	3.7	0
265	Targeted Therapies in Cancer Treatment. , 2021, , 57-78.		1
266	Influence of single nucleotide polymorphisms among cigarette smoking and non-smoking patients with coronary artery disease, urinary bladder cancer and lung cancer. PLoS ONE, 2021, 16, e0243084.	1.1	3
267	Antibody-Based Molecular Imaging. , 2021, , 547-562.		0
268	Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges. Journal of the National Cancer Institute, 2021, 113, 823-832.	3.0	31
269	Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	73
270	Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 401-408.	0.6	9
271	Potentiated antitumor effects of APS001F/5-FC combined with anti-PD-1 antibody in a CT26 syngeneic mouse model. Bioscience, Biotechnology and Biochemistry, 2021, 85, 324-331.	0.6	5
272	Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC. Cancer Immunology, Immunotherapy, 2021, 70, 2179-2195.	2.0	22

#	Article	IF	Citations
273	Oxygenâ€Evolving Manganese Ferrite Nanovesicles for Hypoxiaâ€Responsive Drug Delivery and Enhanced Cancer Chemoimmunotherapy. Advanced Functional Materials, 2021, 31, 2008078.	7.8	65
274	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nature Communications, 2021, 12, 346.	5.8	107
275	Magnetic nanoparticles and clusters for magnetic hyperthermia: optimizing their heat performance and developing combinatorial therapies to tackle cancer. Chemical Society Reviews, 2021, 50, 11614-11667.	18.7	193
276	Immunomodulatory potential of chitosan-based materials for cancer therapy: a systematic review of in vitro, in vivo and clinical studies. Biomaterials Science, 2021, 9, 3209-3227.	2.6	22
277	Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples. , 2021, , 329-350.		0
278	Skin Adverse Reactions from New Cancer Immunotherapy. , 2021, , 355-367.		0
279	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. Frontiers in Oncology, 2020, 10, 601452.	1.3	1
280	Drug delivery systems in cancer therapy. , 2021, , 423-454.		2
281	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. , 2021, , 83-99.		0
282	NEK2 plays an active role in Tumorigenesis and Tumor Microenvironment in Non-Small Cell Lung Cancer. International Journal of Biological Sciences, 2021, 17, 1995-2008.	2.6	13
283	Recent Therapeutic Strategies for the Treatment of Colon Cancer. , 2021, , 73-90.		0
284	Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations. Current Treatment Options in Oncology, 2021, 22, 13.	1.3	12
285	Combination of EP ₄ antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. OncoImmunology, 2021, 10, 1896643.	2.1	28
286	Human Chromosome Telomeres. , 2021, , 207-243.		2
287	Monoclonal Antibodies: A Prospective and Retrospective View. Current Medicinal Chemistry, 2021, 28, 435-471.	1.2	8
289	Acute renal transplant rejection following nivolumab therapy for metastatic melanoma. BMJ Case Reports, 2021, 14, e238037.	0.2	9
290	Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 2433.	1.8	12
291	Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. Journal of Immunology Research, 2021, 2021, 1-15.	0.9	77

#	Article	IF	Citations
292	The Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity. Frontiers in Immunology, 2021, 12, 597761.	2.2	15
294	Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles. Frontiers in Immunology, 2021, 12, 624789.	2.2	34
295	PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation. Frontiers in Oncology, 2020, 10, 614365.	1.3	12
296	Cutaneous immuneâ€related adverse events in patients with melanoma treated with checkpoint inhibitors. British Journal of Dermatology, 2021, 185, 263-271.	1.4	35
297	â€œComplimenting the Complementâ€: Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 627701.	1.3	22
298	Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor. Biomaterials, 2021, 269, 120635.	5.7	31
299	Current advancements and future perspectives of immunotherapy in colorectal cancer research. European Journal of Pharmacology, 2021, 893, 173819.	1.7	91
300	Incidence risk of PD-1/PD-L1â€“related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 2021, 77, 1079-1088.	0.8	9
301	Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation. Drug Development Research, 2021, 82, 730-753.	1.4	5
302	Modeling the tumor immune microenvironment for drug discovery using 3D culture. APL Bioengineering, 2021, 5, 010903.	3.3	14
303	Next generation of immune checkpoint inhibitors and beyond. Journal of Hematology and Oncology, 2021, 14, 45.	6.9	293
305	Using CRISPR to enhance T cell effector function for therapeutic applications. Cytokine: X, 2021, 3, 100049.	0.5	16
306	Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy. OncoTargets and Therapy, 2021, Volume 14, 1981-1988.	1.0	9
307	Identification of a ceRNA Network in Lung Adenocarcinoma Based on Integration Analysis of Tumor-Associated Macrophage Signature Genes. Frontiers in Cell and Developmental Biology, 2021, 9, 629941.	1.8	9
308	Targeting Genome Stability in Melanomaâ€”A New Approach to an Old Field. International Journal of Molecular Sciences, 2021, 22, 3485.	1.8	4
309	Unraveling the Role of Immune Checkpoints in Leishmaniasis. Frontiers in Immunology, 2021, 12, 620144.	2.2	18
310	Mass spectrometry and the cellular surfaceome. Mass Spectrometry Reviews, 2022, 41, 804-841.	2.8	19
311	An Evaluation of the Use of Corticosteroids for the Management of Immune-Mediated Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. Journal of the Advanced Practitioner in Oncology, 2021, 12, 137-145.	0.2	1

#	Article	IF	Citations
312	Prophylactic Cancer Vaccines Engineered to Elicit Specific Adaptive Immune Response. Frontiers in Oncology, 2021, 11, 626463.	1.3	30
313	Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response. Biomedicines, 2021, 9, 402.	1.4	6
314	Immune System Modulations in Cancer Treatment: Nanoparticles in Immunotherapy. , 0, , .		0
315	Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis. Clinical and Translational Oncology, 2021, 23, 1885-1904.	1.2	11
316	Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. Drug Discovery Today, 2021, 26, 951-967.	3.2	25
317	How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 697-717.	2.0	93
318	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 562315.	1.3	38
319	Embracing nanomaterials' interactions with the innate immune system. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1719.	3.3	10
320	Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications. Gynecologic Oncology, 2021, 161, 78-82.	0.6	21
321	TGFÎ²1: An Indicator for Tumor Immune Microenvironment of Colon Cancer From a Comprehensive Analysis of TCGA. Frontiers in Genetics, 2021, 12, 612011.	1.1	3
323	Combined immune checkpoint inhibitors of CTLA4 and PD-1 for hepatic melanoma of unknown primary origin: A case report. World Journal of Clinical Cases, 2021, 9, 2641-2648.	0.3	3
324	Sequence of Î±PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Science Immunology, 2021, 6, .	5.6	81
325	Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies. Journal of Clinical Medicine, 2021, 10, 1919.	1.0	5
326	Postâ€transcriptional control of Tâ€cell cytokine production: Implications for cancer therapy. Immunology, 2021, 164, 57-72.	2.0	3
327	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. Frontiers in Oncology, 2021, 11, 621639.	1.3	12
328	Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations. Expert Opinion on Therapeutic Targets, 2021, 25, 347-363.	1.5	25
329	Cytotoxic T-Lymphocyte-Associated Protein-4 and Lymphocyte Activation Gene-3 Expression in Orbitally-Invasive Versus Nodular Basal Cell Carcinoma. Ophthalmic Plastic and Reconstructive Surgery, 2021, 37, S109-S111.	0.4	4
330	A costâ€utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan. Cancer Reports, 2021, 4, e1399.	0.6	6

#	Article	IF	Citations
331	Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e483-e487.	0.2	1
332	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. International Journal of Molecular Sciences, 2021, 22, 5801.	1.8	182
333	Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment. Frontiers in Oncology, 2021, 11, 628243.	1.3	1
334	Development of new therapeutic options for the treatment of uveal melanoma. FEBS Journal, 2021, 288, 6226-6249.	2.2	19
335	Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patientsâ€"Mechanism of Action and Future Concepts. Cancers, 2021, 13, 2836.	1.7	3
336	Current and Future Scenario of Immunotherapy for the Treatment of Hepatocellular Carcinoma. Current Cancer Therapy Reviews, 2021, 17, 148-158.	0.2	0
337	Formulation and In Vitro Characterization of PLGA/PLGA-PEG Nanoparticles Loaded with Murine Granulocyte-Macrophage Colony-Stimulating Factor. AAPS PharmSciTech, 2021, 22, 191.	1.5	5
338	Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 684-695.	1.3	7
339	Imaging the cellular components of the immune system for advancing diagnosis and immunotherapy of cancers. Materials Today Advances, 2021, 10, 100138.	2.5	1
340	Glycoproteogenomics: Setting the Course for Next-generation Cancer Neoantigen Discovery for Cancer Vaccines. Genomics, Proteomics and Bioinformatics, 2021, 19, 25-43.	3.0	14
341	The Curcumin Analog GO-Y030 Controls the Generation and Stability of Regulatory T Cells. Frontiers in Immunology, 2021, 12, 687669.	2.2	16
342	A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2766-2778.	1.3	9
343	Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review. Interdisciplinary Sciences, Computational Life Sciences, 2021, 13, 801-814.	2.2	7
344	A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. Frontiers in Immunology, 2021, 12, 681984.	2.2	32
345	Targeting Trained Innate Immunity With Nanobiologics to Treat Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1839-1850.	1.1	4
346	Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	30
347	Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma. Future Oncology, 2021, 17, 4115-4129.	1.1	4
348	The impact of preoperative immune checkpoint inhibitors on kidney and bladder cancer surgeries: a systematic reviewâ˜†. Current Problems in Cancer, 2022, 46, 100765.	1.0	2

#	Article	IF	Citations
349	The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs. BMC Cancer, 2021, 21, 829.	1.1	5
350	Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. , 2021, 9, e002256.		18
351	Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer. Trends in Cancer, 2021, 7, 583-593.	3.8	26
352	The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?. Cellular and Molecular Life Sciences, 2021, 78, 6161-6200.	2.4	10
353	Advances in the discovery and development of melanoma drug therapies. Expert Opinion on Drug Discovery, 2021, 16, 1319-1347.	2.5	9
354	Magnetic nanoparticles for cancer theranostics: Advances and prospects. Journal of Controlled Release, 2021, 335, 437-448.	4.8	87
355	Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28â€“Stimulated T Cell IFN-Î³ and TNF-Î± Production. Journal of Immunology, 2021, 207, 436-448.	0.4	1
356	Influence of immunomodulatory drugs on the gut microbiota. Translational Research, 2021, 233, 144-161.	2.2	14
357	Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in Î²-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype. Annals of Hematology, 2021, 100, 2463-2469.	0.8	0
358	New systemic therapies for cutaneous melanoma: why, who and what. Italian Journal of Dermatology and Venereology, 2021, 156, 344-355.	0.1	2
359	Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?. Epigenomes, 2021, 5, 16.	0.8	5
360	Hepatitis B virusâ€“host interactions and novel targets for viral cure. Current Opinion in Virology, 2021, 49, 41-51.	2.6	23
362	Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 1435-1440.	1.3	7
363	Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). International Journal of Oncology, 2021, 59, .	1.4	17
364	Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles. International Journal of Pharmaceutics, 2021, 605, 120816.	2.6	19
365	Fucoidan-Supplemented Diet Potentiates Immune Checkpoint Blockage by Enhancing Antitumor Immunity. Frontiers in Cell and Developmental Biology, 2021, 9, 733246.	1.8	12
366	LRP1B: A Giant Lost in Cancer Translation. Pharmaceuticals, 2021, 14, 836.	1.7	25
367	Intestinal Regulatory T Cells as Specialized Tissue-Restricted Immune Cells in Intestinal Immune Homeostasis and Disease. Frontiers in Immunology, 2021, 12, 716499.	2.2	34

#	Article	IF	Citations
368	Future perspectives on in-vitro diagnosis of drug allergy by the lymphocyte transformation test. Journal of Immunological Methods, 2021, 495, 113072.	0.6	7
369	Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer. Current Medicinal Chemistry, 2022, 29, 1851-1865.	1.2	4
370	Sialic Acid Ligands of CD28 Suppress Costimulation of T Cells. ACS Central Science, 2021, 7, 1508-1515.	5.3	24
371	Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients. Frontiers in Pharmacology, 2021, 12, 742862.	1.6	7
373	PD-L1 on mast cells suppresses effector CD8+ T-cell activation in the skin in murine contact hypersensitivity. Journal of Allergy and Clinical Immunology, 2021, 148, 563-573.e7.	1.5	19
374	Re-Evaluating the Effects of Obesity on Cancer Immunotherapy Outcomes in Renal Cancer: What Do We Really Know?. Frontiers in Immunology, 2021, 12, 668494.	2.2	12
375	The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer. Cells, 2021, 10, 2234.	1.8	10
376	Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1341-1349.	0.4	19
377	Antibody therapy in pancreatic cancer: mAb-ye weâ€™re onto something?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188557.	3.3	6
378	Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 651634.	2.2	47
379	The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges. Targeted Oncology, 2021, 16, 537-552.	1.7	20
380	PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Frontiers in Pharmacology, 2021, 12, 731798.	1.6	134
381	LAMC2 promotes the proliferation of cancer cells and induce infiltration of macrophages in non-small cell lung cancer. Annals of Translational Medicine, 2021, 9, 1392-1392.	0.7	13
382	Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases. Cancers, 2021, 13, 4928.	1.7	10
383	Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy. Cureus, 2021, 13, e17992.	0.2	1
384	Implications of Antigen Selection on T Cell-Based Immunotherapy. Pharmaceuticals, 2021, 14, 993.	1.7	6
385	PD-L1 regulation revisited: impact on immunotherapeutic strategies. Trends in Molecular Medicine, 2021, 27, 868-881.	3.5	30
386	PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies. Medicine and Pharmacy Reports, 0, , .	0.2	10

#	Article	IF	Citations
387	Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacological Research, 2021, 171, 105780.	3.1	196
388	Mathematical Model for Delayed Responses in Immune Checkpoint Blockades. Bulletin of Mathematical Biology, 2021, 83, 106.	0.9	1
389	Immune checkpoints and reproductive immunology: Pioneers in the future therapy of infertility related Disorders?. International Immunopharmacology, 2021, 99, 107935.	1.7	19
390	Local immunotherapy of cancer and metastasis. , 2022, , 483-528.		1
391	Targeted photodynamic immunotherapy. , 2022, , 463-481.		1
392	Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497.		0
393	Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors. Asia-Pacific Journal of Oncology Nursing, 2021, 8, 596-603.	0.7	6
394	Bispecific antibodies: A promising entrant in cancer immunotherapy. , 2021, , 233-266.		2
395	Immunotherapy in non-small cell lung cancer: update and new insights. Journal of Clinical and Translational Research, 0, , .	0.3	23
396	Therapeutic Intervention in Skin Cancer: Future Prospects. , 2021, , 21-40.		0
397	Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. Integrative Cancer Therapies, 2021, 20, 153473542199007.	0.8	25
398	Mediation of Tumor Cell Death by Naked Antibodies. , 2021, , 57-77.		0
399	The Microbiome and Its Implications in Cancer Immunotherapy. Molecules, 2021, 26, 206.	1.7	15
400	Immunotherapy as a boon in cancer treatment. , 2021, , 207-226.		0
401	Targeting the Ubiquitin Signaling Cascade in Tumor Microenvironment for Cancer Therapy. International Journal of Molecular Sciences, 2021, 22, 791.	1.8	21
402	Tollâ€like receptorâ€2/7â€mediated T cell activation: An innate potential to augment CD8 + T cell cytokine production. Scandinavian Journal of Immunology, 2021, 93, e13019.	1.3	9
403	Partial absence of PDâ€1 expression by tumorâ€infiltrating EBVâ€specific CD8⁺ T cells in EBVâ€driven lymphoepitheliomaâ€like carcinoma. Clinical and Translational Immunology, 2020, 9, e1175.	1.7	7
404	Radiotherapy and the immune system: More than just immune suppression. Stem Cells, 2021, 39, 1155-1165.	1.4	61

#	Article	IF	Citations
405	Melanoma Metabolism: Cell Survival and Resistance to Therapy. Advances in Experimental Medicine and Biology, 2020, 1219, 203-223.	0.8	15
406	p110Î´ PI3K as a therapeutic target of solid tumours. Clinical Science, 2020, 134, 1377-1397.	1.8	15
407	In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology. International Journal of Hyperthermia, 2020, 37, 4-17.	1.1	12
409	Domain binding and isotype dictate the activity of anti-human OX40 antibodies. , 2020, 8, e001557.		11
410	Targeting macrophage checkpoint inhibitor SIRPÎ± for anticancer therapy. JCI Insight, 2020, 5, .	2.3	40
411	Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes. JCI Insight, 2020, 5, .	2.3	11
412	Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function. PLoS ONE, 2020, 15, e0243145.	1.1	10
413	Theranostics: Cancer imaging and therapy using injectable radionuclide-labeled ligands. Pharmacy & Pharmacology International Journal, 2020, 8, 325-331.	0.1	2
414	Anticancer Drug-induced Thyroid Dysfunction. European Endocrinology, 2020, 16, 32.	0.8	22
415	Anticancer Medications and Sodium Dysmetabolism. European Endocrinology, 2020, 16, 122.	0.8	9
416	TILRR (FREM1 isoform 2) is a prognostic biomarker correlated with immune infiltration in breast cancer. Aging, 2020, 12, 19335-19351.	1.4	9
417	Pharmacogenetics of anticancer monoclonal antibodies. , 2019, 2, 69-81.		3
418	Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 448-466.	0.7	6
419	Nanoparticles: Properties and Applications in Cancer Immunotherapy. Current Pharmaceutical Design, 2019, 25, 1962-1979.	0.9	12
420	Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes. Current Topics in Medicinal Chemistry, 2020, 20, 1810-1823.	1.0	4
421	Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 100-112.	0.8	16
422	Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. Immunotherapy, 2020, 12, 481-510.	1.0	7
423	Non-coding RNA and immune-checkpoint inhibitors: friends or foes?. Immunotherapy, 2020, 12, 513-529.	1.0	16

#	Article	IF	Citations
424	Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 581107.	1.3	14
425	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies, 2020, 9, 17.	1.2	14
426	The Role of Immune Checkpoints after Cellular Therapy. International Journal of Molecular Sciences, 2020, 21, 3650.	1.8	7
427	Clinical correlation of B7-H3 and B3GALT4 with the prognosis of colorectal cancer. World Journal of Gastroenterology, 2018, 24, 3538-3546.	1.4	25
428	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 230-241.	2.3	284
429	De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma. Cureus, 2019, 11, e5002.	0.2	11
430	Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC. Cell Transplantation, 2021, 30, 096368972110415.	1.2	3
431	Histamine in cancer immunology and immunotherapy. Current status and new perspectives. Pharmacology Research and Perspectives, 2021, 9, e00778.	1.1	20
432	Cancer testis antigen PRAME: An antiâ€cancer target with immunomodulatory potential. Journal of Cellular and Molecular Medicine, 2021, 25, 10376-10388.	1.6	13
433	Improving CAR T-Cell Persistence. International Journal of Molecular Sciences, 2021, 22, 10828.	1.8	44
434	Can Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation?. Journal of NeuroImmune Pharmacology, 2021, , 1.	2.1	2
435	Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 651553.	1.3	3
436	Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharmaceutica Sinica B, 2021, 11, 3727-3739.	5.7	34
437	Contextualizing Genes by Using Text-Mined Co-Occurrence Features for Cancer Gene Panel Discovery. Frontiers in Genetics, 2021, 12, 771435.	1.1	3
438	Onconephrology. , 2022, , 185-209.		0
439	Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From theAJRSpecial Series on Imaging of Inflammation. American Journal of Roentgenology, 2022, 218, 940-952.	1.0	5
440	Cancer and Covid-19: Collectively catastrophic. Cytokine and Growth Factor Reviews, 2022, 63, 78-89.	3.2	10
441	MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy. International Journal of Molecular Sciences, 2021, 22, 11318.	1.8	2

#	Article	IF	Citations
442	ERRFI1 induces apoptosis of hepatocellular carcinoma cells in response to tryptophan deficiency. Cell Death Discovery, 2021, 7, 274.	2.0	10
443	The impact of hypoxia on immune state in cancer. Life Sciences, 2021, 286, 120057.	2.0	46
444	Neoantigen Clonal Balance Predicts Immunotherapy Outcomes and Prognosis. SSRN Electronic Journal, 0, , .	0.4	0
445	Experience of the safety evaluation of the cellular immunotherapy application on basis LAC for canine oncological diseases treatment. Russian Veterinary Journal, 2019, 2019, 13-23.	0.2	0
447	Experience of using atezolizumab in 1st line therapy of metastatic urothelial cancer. Onkourologiya, 2019, 15, 113-119.	0.1	0
449	Hyperprogression of Liver Metastasis With Neoadjuvant Immunotherapy for Soft Tissue Sarcoma. Cureus, 2020, 12, e8575.	0.2	4
451	Influence of Antibiotics on the Antitumor Effect of Immune Checkpoint Inhibitors in Japanese Patients with Non-small-cell Lung Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.1	1
452	The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens. Immuno-Oncology Technology, 2021, 11, 100043.	0.2	9
454	Modulation of intrinsic inhibitory checkpoints using nanoâ€carriers to unleash NK cell activity. EMBO Molecular Medicine, 2022, 14, e14073.	3.3	24
456	Current advances in kidney cancer immunotherapy. Onkourologiya, 2020, 15, 30-38.	0.1	3
457	Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy. Advances in Experimental Medicine and Biology, 2020, 1277, 127-141.	0.8	0
458	CHAPTER 14. Cell and Immune Therapy. RSC Detection Science, 2020, , 303-344.	0.0	0
460	Targeting lung cancer using advanced drug delivery systems. , 2020, , 493-516.		4
462	Gut Microbiota and Cancer Correlates. , 2021, , 1-27.		0
463	Immunotherapy in non-small cell lung cancer: Update and new insights. Journal of Clinical and Translational Research, 2021, 7, 1-21.	0.3	16
464	Atherosclerosis, Ischemia, and Anticancer Drugs. Heart Views, 2021, 22, 127-133.	0.1	1
465	Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives. Journal of Clinical and Translational Research, 2021, 7, 511-522.	0.3	5
466	Immunopharmacogenomics: a hope in the treatment of carcinoma. , 2022, , 327-346.		0

#	Article	IF	Citations
467	Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy. , 2021, 9, e002614.		30
468	Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer â€“ A Case Report. OncoTargets and Therapy, 2021, Volume 14, 5309-5314.	1.0	3
469	Medication-induced Pulmonary Injury: A Scenario- and Pattern-based Approach to a Perplexing Problem. Radiographics, 2022, 42, 38-55.	1.4	11
470	Photodynamic Therapy-Mediated Immune Responses in Three-Dimensional Tumor Models. International Journal of Molecular Sciences, 2021, 22, 12618.	1.8	13
471	Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy. Vaccines, 2021, 9, 1396.	2.1	5
472	Epsteinâ€“Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report. Frontiers in Immunology, 2021, 12, 761798.	2.2	2
473	Cell cycle progression and transmitotic apoptosis resistance promote escape from extrinsic apoptosis. Journal of Cell Science, 2021, 134, .	1.2	6
474	The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. Frontiers in Immunology, 2021, 12, 792691.	2.2	39
475	Impact of immune cells on the hallmarks of cancer: A literature review. Critical Reviews in Oncology/Hematology, 2021, 168, 103541.	2.0	27
477	Resistance to Immunotherapy: Mechanisms and Means for Overcoming. Advances in Experimental Medicine and Biology, 2021, 1342, 45-80.	0.8	2
478	ROS-Mediated Anti-Angiogenic Activity of Cerium Oxide Nanoparticles in Melanoma Cells. ACS Biomaterials Science and Engineering, 2022, 8, 512-525.	2.6	16
480	New Approaches to Dendritic Cell-Based Therapeutic Vaccines Against HIV-1 Infection. Frontiers in Immunology, 2021, 12, 719664.	2.2	8
481	Basics of immunotherapy for epithelial ovarian cancer. Journal of Gynecology Obstetrics and Human Reproduction, 2022, 51, 102283.	0.6	4
482	Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. , 2022, 236, 108103.		20
483	Nanomedicine and Immunotherapy for Cancers. European Journal of Medical and Health Sciences, 2020, 2, .	0.1	0
484	Cancer Defenses in Humans and the Search for a Vaccine. Novel Approaches in Cancer Study, 2020, 5, .	0.2	0
485	Carbonic Anhydrase IX Inhibitors as Candidates for Combination Therapy of Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 13405.	1.8	22
486	Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232110630.	1.1	3

#	Article	IF	Citations
487	Interrogating the interplay of angiogenesis and immunity in metastatic colorectal cancer. World Journal of Methodology, 2022, 12, 43-53.	1.1	7
488	Bystander CD4⁺ T cells infiltrate human tumors and are phenotypically distinct. OncoImmunology, 2022, 11, .	2.1	13
489	CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model. OncoImmunology, 2022, 11, 2019922.	2.1	13
490	Targeting regulatory T cells in antiâ€PDâ€1/PDâ€L1 cancer immunotherapy. Scandinavian Journal of Immunology, 2022, 95, e13129.	1.3	27
491	The emerging role of Arid5a in cancer: A new target for tumors. Genes and Diseases, 2022, , .	1.5	0
492	Complement System: An Immunotherapy Target in Colorectal Cancer. Frontiers in Immunology, 2022, 13, 810993.	2.2	16
493	Nanovesicleâ€Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects. Advanced Materials, 2022, 34, e2106516.	11.1	26
494	Hormone-Related Cancer and Autoimmune Diseases: A Complex Interplay to be Discovered. Frontiers in Genetics, 2021, 12, 673180.	1.1	4
495	Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?. Expert Review of Anticancer Therapy, 2022, 22, 183-189.	1.1	4
496	Annular scaly plaques with peripheral pustules. JAAD Case Reports, 2022, 21, 185-188.	0.4	0
497	Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs). Current Oncology, 2022, 29, 267-282.	0.9	1
498	Directing hypoxic tumor microenvironment and HIF to illuminate cancer immunotherapy's existing prospects and challenges in drug targets. Current Drug Targets, 2022, 23, .	1.0	2
499	Recent Advances in the Role of Arid5a in Immune Diseases and Cancer. Frontiers in Immunology, 2021, 12, 827611.	2.2	6
500	A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease. Life, 2022, 12, 130.	1.1	1
501	Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events. Expert Review of Anticancer Therapy, 2022, 22, 203-213.	1.1	4
502	Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy. Cancer Treatment and Research Communications, 2022, 31, 100529.	0.7	1
503	A negative association of CTLA-4 genetic variant (rs11571317) with breast cancer risk in Moroccan population. Gene Reports, 2022, 26, 101513.	0.4	2
504	Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition. Lung Cancer, 2022, 165, 91-101.	0.9	5

#	Article	IF	Citations
505	Ferroptosis-associated molecular classification characterized by distinct tumor microenvironment profiles in colorectal cancer. International Journal of Biological Sciences, 2022, 18, 1773-1794.	2.6	12
506	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. Seminars in Cancer Biology, 2022, 86, 981-996.	4.3	15
507	Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. Clinical Genitourinary Cancer, 2022, 20, 252-259.	0.9	4
508	Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy. Cancer Cell, 2022, 40, 255-276.	7.7	45
509	Tumor microenvironment-regulated nanoplatforms for the inhibition of tumor growth and metastasis in chemo-immunotherapy. Journal of Materials Chemistry B, 2022, 10, 3637-3647.	2.9	6
510	Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer. Current Cancer Drug Targets, 2022, 22, 639-650.	0.8	2
511	Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?. Journal of Clinical Medicine, 2022, 11, 1019.	1.0	5
513	Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism. Frontiers in Oncology, 2022, 12, 788113.	1.3	18
514	Intratumoral Anti-PD-1 Nanoformulation Improves Its Biodistribution. ACS Applied Materials & Interfaces, 2022, 14, 15881-15893.	4.0	1
515	Circadian and Immunity Cycle Talk in Cancer Destination: From Biological Aspects to In Silico Analysis. Cancers, 2022, 14, 1578.	1.7	7
516	Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression. , 2022, 10, e003721.		6
517	Current Clinical Trial Landscape of OX40 Agonists. Current Oncology Reports, 2022, 24, 951-960.	1.8	15
518	Genesis and Mechanism of Some Cancer Types and an Overview on the Role of Diet and Nutrition in Cancer Prevention. Molecules, 2022, 27, 1794.	1.7	24
519	A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies. Cell Death Discovery, 2022, 8, 106.	2.0	10
520	In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation. Journal of Cardiovascular Translational Research, 2022, , 1.	1.1	2
521	Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy. Cancers, 2022, 14, 1580.	1.7	17
522	Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. , 2022, 10, e004223.		6
523	IL15 and Antiâ€“PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors. Clinical Cancer Research, 2022, 28, 2082-2093.	3.2	4

#	Article	IF	Citations
524	Firstâ€line <scp>PD</scp>â€1/<scp>PDâ€L1</scp> inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced nonâ€squamous nonâ€small cell lung cancer: A Bayesian network metaâ€analysis of randomized controlled trials. Cancer Medicine, 2022, 11, 2043-2055.	1.3	5
525	Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy. Frontiers in Endocrinology, 2022, 13, 779915.	1.5	15
526	Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes. Diabetes Care, 2022, 45, 1170-1176.	4.3	33
527	Efficiency of Electronic Health Record Assessment of Patient-Reported Outcomes After Cancer Immunotherapy. JAMA Network Open, 2022, 5, e224427.	2.8	18
528	Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. Cancers, 2022, 14, 1669.	1.7	6
529	Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy. Biomaterials, 2022, 286, 121510.	5.7	11
530	Functionalized chitosan as a promising platform for cancer immunotherapy: A review. Carbohydrate Polymers, 2022, 290, 119452.	5.1	30
531	Immunotherapy for head and neck cancer: Present and future. Critical Reviews in Oncology/Hematology, 2022, 174, 103679.	2.0	45
533	Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors. Immunotherapy Advances, 2022, 2, .	1.2	5
534	Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review. Academic Radiology, 2022, 29, 1869-1884.	1.3	3
535	Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response. Translational Oncology, 2022, 20, 101405.	1.7	25
536	Red Blood Cell Autoantibodies in Patients Treated with Immune Checkpoint Inhibitors. The Korean Journal of Blood Transfusion, 2021, 32, 201-208.	0.1	1
537	Prognostic significance of natural killer cell-associated markers in gastric cancer: quantitative analysis using multiplex immunohistochemistry. Journal of Translational Medicine, 2021, 19, 529.	1.8	8
538	Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. Cancers, 2021, 13, 6092.	1.7	14
539	Development of Small-Molecule STING Activators for Cancer Immunotherapy. Biomedicines, 2022, 10, 33.	1.4	8
540	Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. Science Advances, 2021, 7, eabj4226.	4.7	11
541	T cells in pancreatic cancer stroma. World Journal of Gastroenterology, 2021, 27, 7956-7968.	1.4	26
543	Autoimmunity regulation within the tumor microenvironment. , 2022, , 51-71.		0

#	Article	IF	Citations
544	From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia. Frontiers in Oncology, 2022, 12, 859071.	1.3	8
545	Activation of T cell checkpoint pathways during Î²â€cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes. Immunology, 2022, 166, 341-356.	2.0	2
546	Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy. Beni-Suef University Journal of Basic and Applied Sciences, 2022, 11, .	0.8	0
547	Immune-Related Adverse Events (irAEs) in Cancer, with Inputs from a Nursing Expert: A Review. Indian Journal of Medical and Paediatric Oncology, 0, 43, .	0.1	0
548	Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy. Frontiers in Oncology, 2022, 12, 834564.	1.3	12
549	Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity. Molecular Cancer Therapeutics, 2022, 21, 948-959.	1.9	14
561	Interferonâ€'stimulated gene 15 promotes progression of endometrial carcinoma and weakens antitumor immune response. Oncology Reports, 2022, 47, .	1.2	4
562	Atherosclerosis, ischemia, and anticancer drugs. Heart Views, 2021, 22, 127.	0.1	2
563	Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination with Checkpoint Inhibitors and Beyond. Current Drug Targets, 2022, 23, .	1.0	1
564	Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology, 2022, 29, 3044-3060.	0.9	239
565	Editorial: Immune-Related Adverse Events for Patients With Lung Cancer. Frontiers in Oncology, 2022, 12, .	1.3	0
566	An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy. Cells, 2022, 11, 1583.	1.8	10
567	Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature. Journal of Clinical Medicine, 2022, 11, 2629.	1.0	6
568	The role of the BTLA-HVEM complex in the pathogenesis of autoimmune diseases. Cellular Immunology, 2022, 376, 104532.	1.4	14
569	Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2022, 13, .	2.2	14
570	Perioperative Systemic Inflammation in Lung Cancer Surgery. Frontiers in Surgery, 2022, 9, .	0.6	3
571	Harnessing chitosan and poly-(Î³-glutamic acid)-based biomaterials towards cancer immunotherapy. Materials Today Advances, 2022, 15, 100252.	2.5	5
572	Melanoma Stem Cell Vaccine Activates Antitumor Immunity by Acting on CD8+T Cells in Multiple Facets. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
573	New Achievements for the Treatment of Triple-Negative Breast Cancer. Applied Sciences (Switzerland), 2022, 12, 5554.	1.3	11
574	YY1 Is a Key Player in Melanoma Immunotherapy/Targeted Treatment Resistance. Frontiers in Oncology, 0, 12, .	1.3	8
577	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. Molecules, 2022, 27, 3798.	1.7	29
578	Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience. Journal of Immunotherapy and Precision Oncology, 2022, , .	0.6	1
579	The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study. International Journal of Molecular Sciences, 2022, 23, 6898.	1.8	1
580	Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis. Molecular Therapy - Oncolytics, 2022, 26, 158-174.	2.0	4
581	Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. Critical Reviews in Oncology/Hematology, 2022, 176, 103746.	2.0	1
582	The Role of Immune Checkpoints in Cancer Progression. , 0, , .		0
583	Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches. Annals of Oncology, 2022, 33, 893-908.	0.6	29
585	Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. Frontiers in Oncology, 0, 12, .	1.3	9
586	Criteria for assessing the response to treatments in solid tumor in the era of new oncology: what radiologists should know. Journal of Radiological Review, 2022, 9, .	0.1	0
587	Microarray-Based Transcriptome Analysis of Peripheral Blood Mononuclear Cells in Lung Cancer Patients. Russian Journal of Genetics, 2022, 58, 814-822.	0.2	0
588	Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide. Pharmaceutics, 2022, 14, 1460.	2.0	2
589	Detection of mutation profiles and tumor mutation burden of cerebrospinal fluid circulating DNA by a cancer genomic panel sequencing in glioma patients. Clinica Chimica Acta, 2022, 534, 81-92.	0.5	4
590	Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors. Cancers, 2022, 14, 3368.	1.7	7
591	Synergistic combination of ritonavir and cisplatin as an efficacious therapy in human cervical cancer cells: a computational drug discovery andinÂvitroinsight. Journal of Biomolecular Structure and Dynamics, 2023, 41, 5802-5816.	2.0	3
592	Tumor necrosis factor alpha and lipopolysaccharides synergistic effects on T-cell immunoglobulin and mucin domain 3 regulation in dendritic cells. Journal of King Saud University - Science, 2022, 34, 102213.	1.6	0
593	In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in mice. Translational Oncology, 2022, 23, 101481.	1.7	2

#	Article	IF	Citations
594	Current knowledge of immunosuppression as a risk factor for skin cancer development. Critical Reviews in Oncology/Hematology, 2022, 177, 103754.	2.0	7
595	Antimelanoma effect of a fucoxylomannan isolated from Ganoderma lucidum fruiting bodies. Carbohydrate Polymers, 2022, 294, 119823.	5.1	13
596	The Role of Cytotoxic T-Lymphocyte Antigen 4 in the Pathogenesis of Multiple Sclerosis. Genes, 2022, 13, 1319.	1.0	3
597	How the Potassium Channel Response of T Lymphocytes to the Tumor Microenvironment Shapes Antitumor Immunity. Cancers, 2022, 14, 3564.	1.7	5
598	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologistsâ€™ Perspectives. Middle East Journal of Digestive Diseases, 2022, 14, 244-253.	0.2	1
599	Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy. Molecules and Cells, 2022, 45, 513-521.	1.0	13
600	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. Human Antibodies, 2022, , 1-20.	0.6	0
601	Interaction of Radiotherapy and Hyperthermia with the Immune System: a Brief Current Overview. Current Stem Cell Reports, 2022, 8, 129-138.	0.7	1
602	Induction of immunogenic cell death in murine colon cancer cells by ferroceneâ€containing redox phospholipid polymers. Cancer Science, 0, , .	1.7	2
603	Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events. Clinical Lung Cancer, 2022, 23, 686-693.	1.1	7
604	Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. Frontiers in Oncology, 0, 12, .	1.3	8
605	Nanomedicines for Overcoming Cancer Drug Resistance. Pharmaceutics, 2022, 14, 1606.	2.0	9
606	Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188775.	3.3	12
607	Progress of CTLA-4 and PD-1 Immune Checkpoint Inhibitors in Treatment for Colorectal Cancer. , 0, 8, 569-575.		0
608	Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	5
609	The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer. International Journal of Molecular Sciences, 2022, 23, 9324.	1.8	7
610	Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies. Cancers, 2022, 14, 3778.	1.7	6
611	Immune checkpoint inhibitors increase the risk of kidney transplant rejection: a real-world pharmacovigilance study. Expert Opinion on Drug Safety, 2023, 22, 231-235.	1.0	3

#	Article	IF	Citations
612	Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art. Cancers, 2022, 14, 4093.	1.7	7
613	Effector Th1 cells under <scp>PD</scp>â€1 and <scp>CTLA</scp>â€4 checkpoint blockade abrogate the upregulation of multiple inhibitory receptors and byâ€pass exhaustion. Immunology, 2022, 167, 640-650.	2.0	3
614	Integrative analyses identify HIF-1Î± as a potential protective role with immune cell infiltration in adamantinomatous craniopharyngioma. Frontiers in Immunology, 0, 13, .	2.2	1
615	Image-guided intratumoral immunotherapy: Developing a clinically practical technology. Advanced Drug Delivery Reviews, 2022, 189, 114505.	6.6	15
616	The interplay between Helicobacter pylori and the gut microbiota: An emerging driver influencing the immune system homeostasis and gastric carcinogenesis. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	25
617	An anti-CTLA-4 heavy chainâ€"only antibody with enhanced T _{reg} depletion shows excellent preclinical efficacy and safety profile. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	13
618	Checkpoint Markers and Tumor Microenvironment: What Do We Know?. Cancers, 2022, 14, 3788.	1.7	7
619	Tumor Microenvironment, Radiology, and Artificial Intelligence: Should We Consider Tumor Periphery?. Journal of Ultrasound in Medicine, 2022, 41, 3079-3090.	0.8	17
620	Combination of microtubule targeting agents with other antineoplastics for cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188777.	3.3	12
621	Identification of cuproptosis-related subtypes, establishment of a prognostic model and tumor immune landscape in endometrial carcinoma. Computers in Biology and Medicine, 2022, 149, 105988.	3.9	15
622	PD-1 expression on mouse intratumoral NK cells and its effects on NK cell phenotype. IScience, 2022, 25, 105137.	1.9	6
623	HSP70 In triple negative breast cancer: Prognostic value and clinical significance. Pathology Research and Practice, 2022, 238, 154127.	1.0	1
624	A cell-laden hydrogel as prophylactic vaccine and anti-PD-L1 amplifier against autologous tumors. Journal of Controlled Release, 2022, 351, 231-244.	4.8	5
625	Background: Immunology and Cancer. Current Clinical Pathology, 2022, , 1-4.	0.0	0
626	Ophthalmology (Eye). , 2022, , 231-253.		0
627	Polyglutamate-based nanoconjugates for image-guided surgery and post-operative melanoma metastases prevention. Theranostics, 2022, 12, 6339-6362.	4.6	0
628	Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Squamous Cell Carcinoma. Journal of Hematology (Brossard, Quebec), 2022, 11, 142-147.	0.4	6
629	A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges. Cancers, 2022, 14, 4166.	1.7	3

#	Article	IF	Citations
630	Boosting the Immune Responseâ€"Combining Local and Immune Therapy for Prostate Cancer Treatment. Cells, 2022, 11, 2793.	1.8	3
631	Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nature Medicine, 2022, 28, 2344-2352.	15.2	79
632	Durable Responses in Patients With Advanced Cholangiocarcinoma on Sequential Dual-agent Immunotherapy After Progressing on Single-agent Immunotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 410-414.	0.6	2
633	Immune checkpoint inhibitors â€“ the revolutionary cancer immunotherapy comes with a cardiotoxic price. Trends in Cardiovascular Medicine, 2024, 34, 71-77.	2.3	6
634	<scp>CD8</scp> + and <scp>FoxP3</scp> + Tâ€Cell Cellular Density and Spatial Distribution After Programmed Deathâ€Ligand 1 Check Point Inhibition. Laryngoscope, 0, , .	1.1	3
635	The Role of Immunotherapy in Pancreatic Cancer. Current Oncology, 2022, 29, 6864-6892.	0.9	18
636	Clinical Presentation and Prognostic Features in Patients with Immunotherapy-Induced Vitiligo-like Depigmentation: A Monocentric Prospective Observational Study. Cancers, 2022, 14, 4576.	1.7	5
637	Molecular characteristics, clinical significance, and cancer immune interactions of cuproptosis and ferroptosis-associated genes in colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	14
638	Immunotherapies of retinoblastoma: Effective methods for preserving vision in the future. Frontiers in Oncology, 0, 12, .	1.3	1
639	The new progress in cancer immunotherapy. Clinical and Experimental Medicine, 2023, 23, 553-567.	1.9	6
640	Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review. Dermatology and Therapy, 2022, 12, 2489-2497.	1.4	7
641	Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice. Frontiers in Immunology, 0, 13, .	2.2	2
642	The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications. Frontiers in Oncology, 0, 12, .	1.3	12
643	A dual-adjuvant neoantigen nanovaccine loaded with imiquimod and magnesium enhances anti-tumor immune responses of melanoma. Biomaterials Science, 2022, 10, 6740-6748.	2.6	5
644	AKT Isoforms as a Target in Cancer and Immunotherapy. Current Topics in Microbiology and Immunology, 2022, , 409-436.	0.7	0
645	Immune Checkpoint Inhibitors in Gastroesophageal Junction or Gastric Cancer. , 2022, , 1-25.		0
646	PD-1 engineered cytomembrane cloaked molybdenum nitride for synergistic photothermal and enhanced immunotherapy of breast cancer. Journal of Materials Chemistry B, 0, , .	2.9	0
647	Immune Checkpoint inhibitor Therapy in Various Cancers. , 0, 14, 318-323.		0

#	Article	IF	Citations
648	AVA-NP-695 Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model. Molecules, 2022, 27, 6721.	1.7	9
650	Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy. Cancer Discovery, 2023, 13, 132-145.	7.7	19
651	CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality. Journal of Hematology and Oncology, 2022, 15, .	6.9	5
652	Heart failure and cancer: From active exposure to passive adaption. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
653	Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. Biomedicines, 2022, 10, 2511.	1.4	10
654	The influence of machine learning technologies in gut microbiome research and cancer studies - A review. Life Sciences, 2022, 311, 121118.	2.0	5
655	Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Frontiers in Oncology, 0, 12, .	1.3	6
656	Effectiveness of immunological agents in nonâ€small cell lung cancer. Cancer Reports, 2023, 6, .	0.6	3
657	Macrophage subsets and their role: co-relation with colony-stimulating factor-1 receptor and clinical relevance. Immunologic Research, 2023, 71, 130-152.	1.3	9
658	Localization and movement of Tregs in gastrointestinal tract: a systematic review. Inflammation and Regeneration, 2022, 42, .	1.5	2
659	BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment. International Journal of Molecular Sciences, 2022, 23, 13424.	1.8	4
660	NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Frontiers in Immunology, 0, 13, .	2.2	4
661	Comprehensive analysis of treatment-related adverse events of immunotherapy in advanced gastric or gastroesophageal junction cancer: A meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 102031.	0.7	2
662	Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer. , 0, , .		0
663	Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy. Cancers, 2022, 14, 5520.	1.7	10
664	Regulatory T Cells in Ovarian Carcinogenesis and Future Therapeutic Opportunities. Cancers, 2022, 14, 5488.	1.7	3
665	Transdermal nanolipoplex simultaneously inhibits subcutaneous melanoma growth and suppresses systemically metastatic melanoma by activating host immunity. Nanomedicine: Nanotechnology, Biology, and Medicine, 2023, 47, 102628.	1.7	2
666	CEACAM1 is a direct SOX10 target and inhibits melanoma immune infiltration and stemness. IScience, 2022, 25, 105524.	1.9	5

#	Article	IF	Citations
667	Curcumin: A Novel Way to Improve Quality of Life for Colorectal Cancer Patients?. International Journal of Molecular Sciences, 2022, 23, 14058.	1.8	2
668	Adjuvant therapy options in renal cell carcinoma â€" targeting the metastatic cascade. Nature Reviews Urology, 2023, 20, 179-193.	1.9	4
669	Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model. International Journal of Molecular Sciences, 2022, 23, 14073.	1.8	8
670	Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade. Cells, 2022, 11, 3534.	1.8	1
671	AMPK activator AICAR in combination with anti-mouse IL10 mAb restores the functionality of intra-tumoral Tfh cells in the 4T1 mouse model. Cellular Immunology, 2022, 382, 104639.	1.4	3
672	Repeated photodynamic therapy mediates the abscopal effect through multiple innate and adaptive immune responses with and without immune checkpoint therapy. Biomaterials, 2023, 292, 121918.	5.7	13
673	Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions. Frontiers in Ophthalmology, 0, 2, .	0.2	3
674	Prediction of immunotherapy efficacy and immunomodulatory role of hypoxia in colorectal cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211383.	1.4	4
675	Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Seminars in Cancer Biology, 2023, 88, 81-95.	4.3	11
676	Endocrine Toxicities Related to Immunotherapy. , 2022, , 1-40.		0
677	Research Progress of Tumor-Associated Macrophages in the Regulation of Breast Cancer Microenvironment. Advances in Clinical Medicine, 2022, 12, 10722-10727.	0.0	0
678	DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress. Cancers, 2022, 14, 5874.	1.7	1
679	Utilizing Biologics in Drug Desensitization. Current Allergy and Asthma Reports, 2023, 23, 1-11.	2.4	6
680	Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer. Nature Communications, 2022, 13, .	5.8	33
681	Immune Checkpoints: The Rising Branch in Cancer Immunotherapy. , 0, , .		0
682	Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient. Diagnostics, 2022, 12, 2864.	1.3	2
683	Identification of antibodies cross-reactive with woodchuck immune cells and activation of virus-specific and global cytotoxic T cell responses by anti-PD-1 and anti-PD-L1 in experimental chronic hepatitis B and persistent occult hepadnaviral infection. Frontiers in Microbiology, 0, 13, .	1.5	1
684	Reproducible and opposing gut microbiome signatures distinguish autoimmune diseases and cancers: a systematic review and meta-analysis. Microbiome, 2022, 10, .	4.9	8

#	Article	IF	Citations
685	Metabolic inhibitor screening identifies dihydrofolate reductase as an inducer of the tumor immune escape mediator CD24. Immunomedicine, 2022, 2, .	0.7	0
686	Exogenous 8-hydroxydeoxyguanosine attenuates doxorubicin-induced cardiotoxicity by decreasing pyroptosis in H9c2 cardiomyocytes. BMC Molecular and Cell Biology, 2022, 23, .	1.0	2
687	Gut microbiota in acute leukemia: Current evidence and future directions. Frontiers in Microbiology, 0, 13, .	1.5	6
688	CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis. Frontiers in Immunology, 0, 13, .	2.2	7
689	Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. Journal of Clinical Medicine, 2022, 11, 7523.	1.0	1
691	Role of T cells in cancer immunotherapy: Opportunities and challenges. , 2023, 1, 116-126.		11
692	Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. Cancers, 2022, 14, 6145.	1.7	10
693	Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions. Expert Opinion on Therapeutic Targets, 2022, 26, 949-961.	1.5	4
694	Characterization of cellular senescence patterns predicts the prognosis and therapeutic response of hepatocellular carcinoma. Frontiers in Molecular Biosciences, 0, 9, .	1.6	5
695	Association of KMT2C/D lossâ€ofâ€function variants with response to immune checkpoint blockades in colorectal cancer. Cancer Science, 2023, 114, 1229-1239.	1.7	10
696	Partners in crime: The feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment. Frontiers in Oncology, 0, 12, .	1.3	1
697	Inhibition or promotion, the potential role of arginine metabolism in immunotherapy for colorectal cancer. International Journal of Transgender Health, 2023, 16, .	1.1	2
698	Hallmarks of Cancer Affected by the MIF Cytokine Family. Cancers, 2023, 15, 395.	1.7	9
699	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis. Journal of Oncology, 2023, 2023, 1-13.	0.6	0
700	TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy. Communications Biology, 2023, 6, .	2.0	5
701	Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review. Frontiers in Neurology, 0, 13, .	1.1	3
702	Neoantigens: promising targets for cancer therapy. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	112
703	Biomaterialâ€Based In Situ Cancer Vaccines. Advanced Materials, 0, , .	11.1	13

#	Article	IF	Citations
704	Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer. Cells, 2023, 12, 258.	1.8	10
705	The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update. Seminars in Cancer Biology, 2023, 89, 1-17.	4.3	6
706	Advancements in Cancer Immunotherapies. Vaccines, 2023, 11, 59.	2.1	8
707	The Role of Immune Checkpoint Inhibitors in Cancer Therapy. Clinics and Practice, 2023, 13, 22-40.	0.6	14
708	New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?. International Journal of Molecular Sciences, 2023, 24, 437.	1.8	10
709	Epigenetic Perspective of Immunotherapy for Cancers. Cells, 2023, 12, 365.	1.8	4
710	Expression of CISH, an Inhibitor of NK Cell Function, Increases in Association with Ovarian Cancer Development and Progression. Biomedicines, 2023, 11, 299.	1.4	0
711	Cytotoxic T-lymphocyte antigen 4 polymorphisms and breast cancer susceptibility: Evidence from a meta-analysis. Journal of the Chinese Medical Association, 2023, 86, 207-219.	0.6	6
712	Clinical Implications of Multi-level (Scalar) Disorganisation in Cancer. , 2023, , 303-313.		0
713	Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma. Frontiers in Medicine, 0, 10, .	1.2	2
714	Injectable Polypeptide Hydrogel Depots Containing Dual Immune Checkpoint Inhibitors and Doxorubicin for Improved Tumor Immunotherapy and Post-Surgical Tumor Treatment. Pharmaceutics, 2023, 15, 428.	2.0	4
715	Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer. Pathology Research and Practice, 2023, 244, 154338.	1.0	3
716	Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report. Biomedicines, 2023, 11, 311.	1.4	3
717	Current Treatment Approaches to Breast Cancer. , 2023, , 23-51.		0
718	Computational analysis of structural and functional evaluation of the deleterious missense variants in the human CTLA4 gene. Journal of Biomolecular Structure and Dynamics, 2023, 41, 14179-14196.	2.0	0
719	Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses. Cancer Letters, 2023, 561, 216139.	3.2	5
720	Therapeutic efficacy of plant-produced Nivolumab in transgenic C57BL/6-hPD-1 mouse implanted with MC38 colon cancer. Biotechnology Reports (Amsterdam, Netherlands), 2023, 38, e00794.	2.1	2
721	Lacticaseibacillus rhamnosus Probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. EBioMedicine, 2023, 91, 104533.	2.7	11

#	Article	IF	Citations
722	Recent Advances in Cancer Immunotherapy Delivery Modalities. Pharmaceutics, 2023, 15, 504.	2.0	5
724	An emerging master inducer and regulator for epithelial-mesenchymal transition and tumor metastasis: extracellular and intracellular ATP and its molecular functions and therapeutic potential. Cancer Cell International, 2023, 23, .	1.8	5
725	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. Cancers, 2023, 15, 1093.	1.7	4
726	Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers, 2023, 15, 1106.	1.7	39
727	Increased Early Cancer Diagnosis: Unveiling Immune-Cancer Biology to Explain Clinical â€œOverdiagnosisâ€• Cancers, 2023, 15, 1139.	1.7	1
728	The immunoregulatory effect of the TREM2-agonist Sulfavant A in human allogeneic mixed lymphocyte reaction. Frontiers in Immunology, 0, 14, .	2.2	1
729	New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. International Journal of Molecular Sciences, 2023, 24, 4044.	1.8	0
730	Advances in antibody-based therapy in oncology. Nature Cancer, 2023, 4, 165-180.	5.7	32
731	Hypercholesterolemia Influences the Progression of Cancer by Changing the Biomolecular and Immunological Status of the Tumor Microenvironment. , 2023, , 1-30.		0
732	Killer to cure: Expression and production costs calculation of tobacco plantâ€made cancerâ€immune checkpoint inhibitors. Plant Biotechnology Journal, 2023, 21, 1254-1269.	4.1	4
733	Immune checkpoint inhibitor using in cases with gestational trophoblastic diseases. , 2023, 40, .		1
735	Self-assembling peptides as immunomodulatory biomaterials. Frontiers in Bioengineering and Biotechnology, 0, 11, .	2.0	6
736	Management of the adverse effects of cancer immunotherapy with a focus on the gastrointestinal and hepatic systems. Journal of the Korean Medical Association, 2023, 66, 112-115.	0.1	0
737	Why Donâ€™t the Mutant Cells That Evade DNA Repair Cause Cancer More Frequently? Importance of the Innate Immune System in the Tumor Microenvironment. International Journal of Molecular Sciences, 2023, 24, 5026.	1.8	2
738	Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins. International Journal of Molecular Sciences, 2023, 24, 4961.	1.8	2
739	Current landscape and tailored management of immune-related adverse events. Frontiers in Pharmacology, 0, 14, .	1.6	1
740	Tumor-infiltrating regulatory TÂcells as targets of cancer immunotherapy. Cancer Cell, 2023, 41, 450-465.	7.7	60
741	Novel approaches to managing gestational trophoblastic tumors in the age of immunotherapy. International Journal of Gynecological Cancer, 2023, 33, 414-419.	1.2	2

#	Article	IF	Citations
742	Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression. Journal of Clinical Investigation, 2023, 133, .	3.9	10
743	A Therapeutic Vaccine in Combination with Cyclic GMPâ€“AMP Cures More Differentiated Melanomas in Mice. Journal of Immunology, 2023, 210, 1428-1436.	0.4	3
744	A New Frontier of Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. Advances in Clinical Medicine, 2023, 13, 4382-4388.	0.0	0
745	Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance. Cardio-Oncology, 2023, 9, .	0.8	1
746	Effect of Anticancer Treatment Approaches on Gut Microbiota. , 2023, , 41-59.		0
747	An immune checkpoint-based signature predicts prognosis and chemotherapy response for patients with small cell lung cancer. International Immunopharmacology, 2023, 117, 109827.	1.7	1
748	The efficacy and safety of firstâ€line antiâ€PDâ€1/PDâ€L1 immunotherapy for gastric esophageal cancer: A systematic review and metaâ€analysis of phase III randomized controlled trials. Experimental and Therapeutic Medicine, 2023, 25, .	0.8	0
749	Emerging hallmark of gliomas microenvironment in evading immunity: a basic concept. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2023, 59, .	0.4	1
750	The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2023, 24, 6710.	1.8	7
751	Cancer immune escape: the role of antigen presentation machinery. Journal of Cancer Research and Clinical Oncology, 2023, 149, 8131-8141.	1.2	6
752	Immunotherapeutic and their immunological aspects: Current treatment strategies and agents. National Journal of Maxillofacial Surgery, 2022, 13, 322.	0.1	1
753	Development of a Highly Sensitive Hybrid LC/MS Assay for the Quantitative Measurement of CTLA-4 in Human T Cells. Molecules, 2023, 28, 3311.	1.7	0
754	Leveraging Advancement in Robotics in the Treatment of Cancer. Biological and Medical Physics Series, 2023, , 365-404.	0.3	0
755	Discovery of First-in-Class Small Molecule Inhibitors of Lymphocyte Activation Gene 3 (LAG-3). ACS Medicinal Chemistry Letters, 2023, 14, 629-635.	1.3	6
756	Cutaneous manifestations induced by check point inhibitors in 120 melanoma patientsâ€”The European MelSkinTox study. Journal of the European Academy of Dermatology and Venereology, 2023, 37, 1606-1615.	1.3	3
757	Melanoma stem cell vaccine induces effective tumor immunity against melanoma. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	4
758	Tumor-associated fibrosis impairs the response to immunotherapy. Matrix Biology, 2023, 119, 125-140.	1.5	4
765	Development and therapeutic applications of monoclonal antibodies. , 2023, , 99-114.		0

#	Article	IF	Citations
775	Transforming Diagnosis and Therapeutics Using Cancer Genomics. Cancer Treatment and Research, 2023, , 15-47.	0.2	1
791	Monoclonal Antibodies in Oncology: A Decade of Novel Options. Cell Biochemistry and Biophysics, 0, , .	0.9	1
798	Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil. Clinical Journal of Gastroenterology, 2023, 16, 720-725.	0.4	2
800	Macrophage-mimetic nanomedicines for the treatment of diseases. , 2023, , 63-89.		0
805	Circulating tumor cells and host immunity: A tricky liaison. International Review of Cell and Molecular Biology, 2023, , 131-157.	1.6	0
823	Polymer-mediated nanoformulations: a promising strategy for cancer immunotherapy. Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397, 1311-1326.	1.4	0
825	Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics. Clinical and Experimental Medicine, 2023, 23, 4297-4322.	1.9	2
830	Approaches to Generating Virtual Patient Cohorts with Applications in Oncology. , 2023, , 97-119.		1
831	Therapeutic antibodies against cancerâ€"A step toward the treatment. , 2024, , 3-29.		0
838	PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunology, Immunotherapy, 2023, 72, 3875-3893.	2.0	4
849	Molecular insight into renal cancer and latest therapeutic approaches to tackle it: anÂupdatedÂreview. , 2023, 40, .		0
850	Pulmonary Toxicity Associated with Immune CheckpointÂInhibitors-Based Therapy: Current Perspectives and Future Directions. Drug Safety, 2023, 46, 1313-1322.	1.4	1
854	TO MARKET, TO MARKETâ€"2022: MACROMOLECULAR THERAPEUTICS. Medicinal Chemistry Reviews, 0, , 713-798.	0.1	0
855	Comprehensive genomic profiling for oncological advancements by precision medicine. , 2024, 41, .		2
868	T Lymphocyte Metabolic Features and Techniques to Modulate Them. Biochemistry (Moscow), 2023, 88, 1857-1873.	0.7	0
869	Microphysiological systems for solid tumor immunotherapy: opportunities and challenges. Microsystems and Nanoengineering, 2023, 9, .	3.4	1
878	Endocrine Complications of the Hematologic Disorders and of Their Treatment. , 2024, , .		0
884	Exploring the next generation of antibodyâ€"drug conjugates. Nature Reviews Clinical Oncology, 2024, 21, 203-223.	12.5	5

#	Article	IF	Citations
885	Associations between HIFs and tumor immune checkpoints: mechanism and therapy. Discover Oncology, 2024, 15, .	0.8	1
886	Technological evolution in cancer diagnosis and therapeutics. , 2024, , 33-54.		0
887	CAR-T cell therapy: a game-changer in cancer treatment and beyond. Clinical and Translational Oncology, 0, , .	1.2	0
892	Current status and future prospective of breast cancer immunotherapy. Advances in Protein Chemistry and Structural Biology, 2024, , .	1.0	0
896	Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade. Clinical and Experimental Metastasis, 0, , .	1.7	0
899	Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. Molecular Biology Reports, 2024, 51, .	1.0	1
926	Exploring the Therapeutic Potential of ICOS and GITR Agonists in Lung Cancer. , 2024, , 201-213.		0